Gastro Esophageal Junction Cancer Recruiting Phase 2 Trials for Docetaxel (DB01248)

Back to Gastro Esophageal Junction Cancer

Also known as: Gastroesophageal-junction Cancer / Gastroesophageal Junction Cancer / Gastro-oesophageal Junction Cancer / Gastro-esophageal Junction Cancer / Gastrooesophageal junction cancer / Carcinoma of oesophagus NOS / Carcinoma of oesophagus / Carcinoma of esophagus (disorder) / Carcinoma of esophagus / Oesophageal carcinoma NOS / Oesophageal carcinoma / Esophageal carcinoma NOS / Esophageal carcinoma / Primary malignant neoplasm of esophagus (disorder)

Indication	Status	Phase
DBCOND0106887 (Gastro Esophageal Junction Cancer)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03448835	Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)	Treatment	Atezolizumab (DB11595) Capecitabine (DB01101) Docetaxel (DB01248) Oxaliplatin (DB00526)